Aromatase Inhibitors vs Tamoxifen for Breast Cancer
Author Information
Author(s): Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri E M, Milella M, Ciccarese M, Cecere F L, Gelibter A, Nuzzo C, Cognetti F, Terzoli E, Carlini P
Primary Institution: Regina Elena Cancer Institute, Rome, Italy
Hypothesis
Are aromatase inhibitors more effective than tamoxifen as first-line therapy for postmenopausal women with metastatic breast cancer?
Conclusion
Aromatase inhibitors are superior to tamoxifen in improving overall response rate, clinical benefit, and time to progression in postmenopausal women with metastatic breast cancer.
Supporting Evidence
- Aromatase inhibitors showed a significant advantage in overall response rate compared to tamoxifen.
- Time to progression was significantly longer for patients treated with aromatase inhibitors.
- Clinical benefit was significantly higher in the aromatase inhibitor group.
Takeaway
This study found that aromatase inhibitors work better than tamoxifen for women with certain types of breast cancer.
Methodology
The study analyzed data from six phase III randomized trials comparing aromatase inhibitors to tamoxifen in postmenopausal women with metastatic breast cancer.
Potential Biases
Potential bias due to variability in trial designs and patient characteristics across studies.
Limitations
The results showed significant heterogeneity among the trials, which may affect the reliability of the conclusions.
Participant Demographics
Postmenopausal women with hormone receptor-positive metastatic breast cancer.
Statistical Information
P-Value
P=0.001 for clinical benefit, P=0.007 for time to progression, P=0.042 for overall response rate.
Confidence Interval
95% CI 1.00–1.28 for overall response rate, 95% CI 0.80–0.96 for time to progression, 95% CI 1.04–1.19 for clinical benefit.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website